Search
Embusartan
go.drugbank.com/drugs/DB19949ExperimentalEmbusartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Embusartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic). … Embusartan has a monoisotopic molecular weight of 461.19 Da.
Categories: Angiotensin II Type 1 Receptor Blockers, Heterocyclic Compounds, 1-RingTTP889
go.drugbank.com/drugs/DB05131InvestigationalTTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. … TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders.
Valoctocogene roxaparvovec
go.drugbank.com/drugs/DB15561ApprovedInvestigationalWithdrawnValoctocogene roxaparvovec is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector that expresses the B-domain deleted SQ form of human coagulation factor VIII (hFVIII-SQ). … [L43282] The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active factor VIII in blood.
Synonyms: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)Risdiplam
go.drugbank.com/drugs/DB15305ApprovedInvestigationalRisdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). … [L15331,L15336] Set to be substantially cheaper than other available SMA therapies,[L15351] risdiplam appears to provide a novel and relatively accessible treatment option for patients with SMA regardless
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsIopodic acid
go.drugbank.com/drugs/DB09333ApprovedWithdrawnIopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6. … This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.
Categories: X-Ray Contrast Media, Iodinated, Watersoluble, Hepatotropic X-Ray Contrast MediaZiconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigationalZiconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail _Conus magus_ comprising 25 amino acids with three disulphide bonds. … [A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.
Categories: Calcium Channels, N-Type, N-Calcium Channel Receptor AntagonistsTrastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigationalTrastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. … [L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.
Synonyms: T-DXd, T- DXdCategories: MATE 2 Substrates, P-glycoprotein substratesNadolol
go.drugbank.com/drugs/DB01203ApprovedInvestigationalNadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.
Mixtures: Corzide Tab W Nadolol 80mg, Corzide Tab W Nadolol 40mgCategories: MATE 1 Substrates, MATE 2 SubstratesTazemetostat
go.drugbank.com/drugs/DB12887ApprovedInvestigationalTazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Categories: MATE 2-K Inhibitors, MATE 1 InhibitorsQuinapril
go.drugbank.com/drugs/DB00881ApprovedInvestigationalQuinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure. … [L8420] A combination tablet with [hydrochlorothiazide] was also approved on 28 December 1999.[L8423]
Mixtures: QUINAPRIL E IDROCLOROTIAZIDE ACTAVIS, QUINAPRIL E IDROCLOROTIAZIDE MYLAN GENERICSCategories: Heterocyclic Compounds, 2-Ring